399 filings
Page 4 of 20
6-K
SPRC
SciSparc Ltd
21 Jun 23
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
9:08am
6-K
SPRC
SciSparc Ltd
16 Jun 23
Report of Foreign Private Issuer
9:09am
6-K
SPRC
SciSparc Ltd
12 Jun 23
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
7:02am
6-K
SPRC
SciSparc Ltd
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
SPRC
SciSparc Ltd
30 May 23
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
4:01pm
6-K
SPRC
SciSparc Ltd
16 May 23
At-The-Market Issuance Sales Agreement
8:06pm
424B5
SPRC
SciSparc Ltd
16 May 23
Prospectus supplement for primary offering
5:30pm
6-K
SPRC
SciSparc Ltd
8 May 23
Report of Foreign Private Issuer
8:23am
6-K
SPRC
SciSparc Ltd
5 May 23
Report of Foreign Private Issuer
4:01pm
6-K
SPRC
SciSparc Ltd
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
20-F
2022 FY
SPRC
SciSparc Ltd
Annual report (foreign)
1 May 23
4:02pm
6-K
SPRC
SciSparc Ltd
21 Apr 23
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
9:12am
6-K
SPRC
SciSparc Ltd
4 Apr 23
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
5:48pm
6-K
SPRC
SciSparc Ltd
4 Apr 23
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
7:07am
EFFECT
SPRC
SciSparc Ltd
16 Mar 23
Notice of effectiveness
12:15am
6-K
SPRC
SciSparc Ltd
10 Mar 23
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
5:00pm
POS AM
SPRC
SciSparc Ltd
9 Mar 23
Prospectus update (post-effective amendment)
4:15pm
6-K
SPRC
SciSparc Ltd
7 Mar 23
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
6:02am
6-K
SPRC
SciSparc Ltd
27 Feb 23
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
9:13am
6-K
SPRC
SciSparc Ltd
27 Feb 23
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
7:46am